All reports
Pharmaceutical
Oncology, Cell & Gene Therapy
Immuno-Oncology: Checkpoint Inhibitors and Combinations
Code: NSC/PHRM/0009Published Apr 10, 2026Data window: 12 months
About this report
Upcoming Keytruda biosimilars, Opdivo+Yervoy, ivonescimab (Akeso/Summit): winning combinations.
Humans at the core of the analysis
Partner specialist firms, independent domain experts and our in-house analyst team: every report is written and reviewed by humans who cross-check signals, verify sources and prioritise what matters.
Key insights
Request the sample to discover the report's key insights.
Table of contents
The detailed table of contents is shared with the free sample.